X.T.L. Biopharmaceuticals Ltd ADR
XTLBHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 3:59 PM ET
1.66-0.05 (-2.64%)
2026-11-12 00:38 CET
Market cap
7.64 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-0.77 USD m
Free cash flow, TTM
-1.03 USD m
EPS diluted, TTM
-0.34
P/E
-
Price
XTLB against its 20, 50 and 200-day averages2050200
70.6% under the 52-week high of 5.64 on 13 Jan 2026. 52-week low 1.52 on 9 Nov 2026. Last 15 sessions, 38.2% high to low
Volume 0.64× normal · the line is the 50-bar volume average
Profile
XTLB52-week range, 3% of the way up
1.525.64
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
| Employees | 6 |
|---|---|
| IPO | Sep 01, 2005 |
| Beta | 1.49 |
| ATR, 14d | 0.21 |
| Rel volume | 0.64 |
| Short float | 0.10% |
| Insider own | 2.46% |
| Inst own | 0.22% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 7.44M |
| Enterprise Value | - |
| Income | - |
| Sales | - |
| Book/sh | - |
| Cash/sh | - |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 6 |
| IPO | Sep 01, 2005 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | - |
| P/C | - |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | - |
| Current Ratio | - |
| Debt/Eq | - |
| LT Debt/Eq | - |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | - |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | 29.65% 31.74% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 65.58% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 44.39% |
| Sales Q/Q | - |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 2.46% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 0.22% |
| Inst Trans | -99.73% |
| ROA | - |
| ROE | - |
| ROIC | - |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | -7.57% |
| SMA50 | -20.47% |
| SMA200 | -37.06% |
| Trades | - |
Technical
| Shs Outstand | 4.48M |
|---|---|
| Shs Float | 4.37M |
| Short Float | 0.10% |
| Short Ratio | 0.47 |
| Short Interest | 0.00M |
| 52W High | 5.64 -70.57% |
| 52W Low | 1.52 9.21% |
| Volatility | 19.25% 9.92% |
| ATR (14) | 0.21 |
| RSI (14) | 41.31 |
| Beta | 1.49 |
| Rel Volume | 0.64 |
| Avg Volume | 9.07K |
| Volume | 5,811 |
Performance
| Perf Week | -2.35% |
|---|---|
| Perf Month | -16.16% |
| Perf Quarter | -40.71% |
| Perf Half Y | -39.19% |
| Perf YTD | -28.45% |
| Perf Year | -58.09% |
| Perf 3Y | -48.54% |
| Perf 5Y | -88.41% |
| Perf 10Y | -89.62% |
| Recom | 1.00 |
| Target Price | 6.00 |
| Prev Close | 1.71 |
| Price | 1.66 |
| Change % | -2.64% |
Analyst ratings
latest 1 of 1| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 08, 2015 | Initiated | HH.C. Wainwright | Buy | $6 | +261.4% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| CMND | Clearmind Medicine Inc | 2.51M |
| PBM | Psyence Biomedical Ltd | 12.13M |
| ENVB | Enveric Biosciences Inc | 6.67M |
| SILO | SILO Pharma Inc | 2.92M |
| HELP | Helus Pharma Inc | 686.03M |
| DFTX | Definium Therapeutics Inc | 4.72B |
| GHRS | GH Research PLC | 1.32B |
| QNTM | Quantum BioPharma Ltd | 15.69M |
| DRUG | Bright Minds Biosciences Inc | 231.32M |
| SPRC | SciSparc Ltd | 0.82M |
News
latest 14 of 186- XTL Completed the Acquisition of Psyga Bio Ltd. (GlobeNewswire) +15.68% -8.79%
- XTL Announces Receipt of Staff Delist Determination from Nasdaq (GlobeNewswire) -5.18%
- XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies (GlobeNewswire) +54.78%
- XTL Biopharmaceuticals Announces ADS Ratio Change (GlobeNewswire)
- XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing (GlobeNewswire)
- XTL Update on Recent Developments (GlobeNewswire) -5.81%
- XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency (GlobeNewswire) -10.08%
- Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments (Benzinga) +56.66%
- XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership (GlobeNewswire)
- XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -5.74%
- XTL Names Mr. Noam Band as its New Chief Executive Officer (GlobeNewswire) -11.42%
- XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million (GlobeNewswire)
- Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +19.61%
- XTL Entered Definitive Agreement to Acquire The Social Proxy (GlobeNewswire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| No quarterly earnings. | |||||||
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2014FY | -0.200 | - | - | 0.00 | - |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual | -0.806 | 2.316 | -1.051 | -2.312 | 0.328 | -0.984 | -1.305 | -0.615 | -0.343 |
|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| EPS, quarterly | -0.547 | -0.67 | -0.265 | -0.155 | -0.21 | 0.36 | -0.514 | -0.177 | -0.117 |
| Period | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.162 | 0.291 |
| Period | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
| Shares, annual | 1.286 | 1.286 | 1.286 | 1.286 | 1.362 | 1.362 | 1.362 | 2.203 | 2.366 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Shares, quarterly | 1.362 | 1.362 | 1.362 | 1.362 | 1.362 | 1.362 | 1.362 | 3.136 | 2.203 |
| Period | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -0.20 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 1.48 | 1.48 | 0.58 | 0.76 | 0.88 | 1.03 | 0.95 | 0.84 | 0.79 |
| Research and Development | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.48 | -1.48 | -0.78 | -0.76 | -0.88 | -1.03 | -0.95 | -0.84 | -0.79 |
| Non-Operating Income (Expense) | -0.09 | -0.09 | 0.01 | 0.01 | 0.02 | 0.02 | 0.05 | 0.10 | 0.06 |
| Interest Expense | 0.03 | 0.03 | 0.09 | 0.00 | 0.01 | 0.02 | 0.02 | 0.03 | 0.01 |
| Unusual Expense | -0.84 | -0.84 | -1.10 | 1.02 | 0.48 | -1.47 | 2.05 | 0.58 | -3.71 |
| Net Income Before Taxes | -0.77 | -0.77 | 0.24 | -1.78 | -1.34 | 0.44 | -2.97 | -1.35 | 2.98 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -0.77 | -0.77 | 0.24 | -1.78 | -1.34 | 0.44 | -2.97 | -1.35 | 2.98 |
| Net Income From Continuing Operations | -0.77 | -0.77 | 0.24 | -1.78 | -1.34 | 0.44 | -2.97 | -1.35 | 2.98 |
| Net Income | -0.77 | -0.77 | -1.03 | -1.78 | -1.34 | 0.44 | -2.97 | -1.35 | 2.98 |
| EPS (Recurring) | -0.60 | -0.60 | -1.07 | -0.78 | -0.74 | -0.44 | -1.20 | -0.74 | 0.29 |
| EPS (Basic, Before Extraordinaries) | -0.34 | -0.34 | -0.61 | -1.30 | -0.98 | 0.33 | -2.31 | -1.05 | 2.32 |
| EPS (Diluted) | -0.34 | -0.34 | -0.61 | -1.30 | -0.98 | 0.33 | -2.31 | -1.05 | 2.32 |
| EBITDA | -1.48 | -1.48 | -0.58 | -0.76 | -0.88 | -1.03 | -0.95 | - | - |
| Stock Option Compensation Expense | 0.27 | 0.27 | 0.20 | 0.00 | 0.01 | 0.04 | 0.05 | 0.01 | 0.02 |
| Price To Earnings Ratio | - | - | - | - | 4.17 | 34.30 | - | - | 2.99 |
| Price To Sales Ratio | - | - | 30.09 | - | - | - | - | - | - |
| Shares Outstanding | - | 2.37 | 2.20 | 1.36 | 1.36 | 1.36 | 1.29 | 1.29 | 1.29 |
| Market Capitalization | 7.64 | 7.64 | 17.86 | 5.50 | 6.59 | 15.09 | 15.58 | 7.04 | 8.90 |
Income statement, quarterly
| Metric | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | - | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | - | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | - | 0.81 | 0.42 | 0.18 | 0.20 | 0.15 | 0.16 | 0.25 |
| Research and Development | - | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | -0.77 | -0.42 | -0.18 | -0.20 | -0.15 | -0.16 | -0.25 |
| Interest Expense | - | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | - | -0.29 | 0.28 | -0.67 | 0.15 | 0.04 | 0.18 | 0.65 |
| Net Income Before Taxes | - | -0.55 | -0.70 | 0.49 | -0.29 | -0.21 | -0.36 | -0.91 |
| Income Taxes | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | - | -0.55 | -0.70 | 0.49 | -0.29 | -0.21 | -0.36 | -0.91 |
| Net Income From Continuing Operations | - | -0.55 | -0.70 | 0.49 | -0.29 | -0.21 | -0.36 | -0.91 |
| Net Income | - | -0.55 | -0.70 | 0.49 | -0.29 | -0.21 | -0.36 | -0.91 |
| EPS (Recurring) | - | -0.24 | -0.37 | 0.01 | -0.14 | -0.13 | -0.17 | -0.33 |
| EPS (Basic, Before Extraordinaries) | - | -0.18 | -0.51 | 0.36 | -0.21 | -0.16 | -0.26 | -0.67 |
| EPS (Diluted) | - | -0.18 | -0.51 | 0.36 | -0.21 | -0.16 | -0.26 | -0.67 |
| EBITDA | - | - | -0.42 | -0.18 | - | - | - | -0.25 |
| Non-Operating Income (Expense) | - | -0.08 | -0.00 | -0.01 | 0.06 | -0.02 | -0.02 | -0.01 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price To Sales Ratio | - | 185.66 | - | - | - | - | - | - |
| Gross Margin | - | 28.40 | - | - | - | - | - | - |
| Operating Margin | - | -471.61 | - | - | - | - | - | - |
| Net Margin | - | -341.36 | - | - | - | - | - | - |
| Shares Outstanding | - | 3.14 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
| Market Capitalization | - | 30.17 | 13.24 | 15.31 | 5.50 | 4.89 | 5.45 | 7.14 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.08 | 1.14 | 2.01 | 3.72 | 6.13 | 6.04 | 6.73 | 8.12 | 6.09 |
| Short Term Receivables | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.09 | 0.10 | 0.04 | 0.09 | 0.11 | 0.08 | 0.10 | 0.05 | 0.09 |
| Total Current Assets | 0.17 | 1.34 | 2.05 | 3.81 | 6.24 | 6.12 | 6.83 | 8.19 | 6.21 |
| Net Property, Plant & Equipment | 0.00 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 7.01 | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 |
| Other Assets | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 0.17 | 8.55 | 2.43 | 4.19 | 6.62 | 6.50 | 7.21 | 8.57 | 6.59 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.27 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 0.02 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Other Current Liabilities | 0.13 | 1.87 | 0.21 | 0.19 | 0.23 | 0.25 | 0.23 | 0.24 | 0.30 |
| Total Current Liabilities | 0.42 | 2.21 | 0.21 | 0.19 | 0.23 | 0.25 | 0.23 | 0.25 | 0.30 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Deferred Tax Liabilities | - | 0.22 | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.69 | 0.00 | 0.00 | 1.05 | 2.64 | 0.00 | 0.00 | 2.67 |
| Total Liabilities | 0.42 | 3.11 | 0.21 | 0.19 | 1.29 | 2.89 | 0.23 | 0.25 | 2.97 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -0.25 | 5.43 | 2.22 | 4.00 | 5.33 | 3.61 | 6.98 | 8.32 | 3.62 |
| Total Shareholders Equity | -0.25 | 5.43 | 2.22 | 4.00 | 5.33 | 3.61 | 6.98 | 8.32 | 3.62 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -0.25 | 5.43 | 2.22 | 4.00 | 5.33 | 3.61 | 6.98 | 8.32 | 3.62 |
| Total Liabilities & Stockholders Equity | 0.17 | 8.55 | 2.43 | 4.19 | 6.62 | 6.50 | 7.21 | 8.57 | 6.59 |
| Book Value Per Share | -0.11 | 2.47 | 1.63 | 2.94 | 3.91 | 2.81 | 5.43 | 6.47 | 2.82 |
| Tangible Book Value Per Share | -0.11 | -0.71 | 1.35 | 2.66 | 3.64 | 2.51 | 5.13 | 6.18 | 2.52 |
| Full-Time Employees | 6 | 11 | 8 | 8 | 8 | 8 | 4 | 6 | 6 |
| Price to Book Ratio | 0.69 | 3.29 | 2.20 | 1.39 | 2.83 | 2.49 | 1.01 | 1.07 | 3.25 |
| Return on Assets | -17.55 | 4.39 | -53.76 | -24.86 | 6.64 | -43.38 | -17.12 | 39.26 | -16.39 |
| Return on Equity | -29.53 | 6.30 | -57.16 | -28.78 | 7.52 | -56.17 | -17.66 | 49.85 | -24.96 |
| Return on Invested Capital | - | -18.99 | -80.06 | -33.58 | 8.16 | -82.36 | -19.36 | 35.76 | -21.75 |
| Quick Ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 |
| Current Ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -7.02 | -7.02 | -1.03 | -1.78 | -1.34 | 0.44 | -2.97 | -1.35 | 2.98 |
| Depreciation | 0.00 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Deferred Taxes & Investment Tax Credit | 0.00 | 0.00 | -0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | 5.99 | 5.99 | -0.82 | 1.05 | 0.50 | -1.42 | 2.11 | 0.58 | -3.71 |
| Funds from Operations | -1.03 | -1.03 | -1.78 | -0.73 | -0.84 | -0.99 | -0.87 | -0.77 | -0.73 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.00 | -0.00 | 0.19 | 0.06 | -0.02 | -0.05 | 0.05 | -0.05 | -0.01 |
| Cash from Operating Activities | -1.03 | -1.03 | -1.59 | -0.66 | -0.86 | -1.04 | -0.82 | -0.82 | -0.74 |
| Capital Expenditures | 0.00 | 0.00 | -0.05 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | -0.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.78 | 0.78 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 2.03 | 0.70 |
| Purchase of Investments | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.28 |
| Sale Or Maturity of Investments | 0.78 | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.03 | 6.98 |
| Other Uses | -0.26 | -0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.53 | 0.53 | -0.88 | 0.00 | 0.00 | 0.00 | -0.00 | 2.02 | 0.70 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.00 | 1.47 | 0.00 | 0.00 | 0.39 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.00 | 1.47 | 0.00 | 0.00 | 0.39 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.21 | 0.21 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.21 | 0.21 | 1.45 | 0.00 | 0.00 | 0.39 | 0.00 | 0.00 | 0.00 |
| Exchange Rate Effect | 0.00 | 0.00 | -0.02 | -0.03 | -0.01 | -0.01 | -0.01 | -0.00 | 0.00 |
| Net Change in Cash | -0.30 | -0.30 | -1.03 | -0.69 | -0.87 | -0.66 | -0.83 | 1.20 | -0.03 |
| Free Cash Flow | -1.03 | -1.03 | -1.65 | -0.66 | -0.86 | -1.04 | -0.82 | -0.82 | -0.74 |
Balance sheet, quarterly
| Metric | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | - | 1.72 | 1.59 | 2.34 | 2.01 | 2.21 |
| Short Term Receivables | - | 0.14 | 0.30 | 0.15 | 0.00 | 0.00 |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | - | 0.13 | 0.13 | 0.06 | 0.04 | 0.08 |
| Total Current Assets | - | 1.99 | 2.02 | 2.55 | 2.05 | 2.28 |
| Net Property, Plant & Equipment | - | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | 7.08 | 0.38 | 0.38 | 0.38 | 0.38 |
| Other Assets | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | - | 9.28 | 2.40 | 2.93 | 2.43 | 2.66 |
| Short Term Debt Incl. Current Port. of LT Debt | - | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | - | 0.55 | 0.17 | 0.22 | 0.21 | 0.16 |
| Other Current Liabilities | - | 1.75 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | - | 2.47 | 0.17 | 0.22 | 0.21 | 0.16 |
| Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | 0.33 | - | - | - | - |
| Other Liabilities | - | 0.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | - | 3.56 | 0.17 | 0.22 | 0.21 | 0.16 |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | - | 5.72 | 2.23 | 2.71 | 2.22 | 2.50 |
| Total Shareholders Equity | - | 5.72 | 2.23 | 2.71 | 2.22 | 2.50 |
| Accumulated Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | - | 5.72 | 2.23 | 2.71 | 2.22 | 2.50 |
| Total Liabilities & Stockholders Equity | - | 9.28 | 2.40 | 2.93 | 2.43 | 2.66 |
| Book Value Per Share | - | 1.82 | 1.64 | 1.99 | 1.63 | 1.84 |
| Tangible Book Value Per Share | - | -0.43 | 1.36 | 1.71 | 1.35 | 1.56 |
| Full-Time Employees | - | - | - | - | 8 | - |
| Price to Book Ratio | - | 5.28 | 4.89 | 6.90 | 2.20 | 1.80 |
| Return on Assets | - | -17.63 | -26.98 | -11.86 | -53.58 | -59.01 |
| Return on Equity | - | -25.62 | -28.77 | -12.81 | -56.97 | -61.58 |
| Return on Invested Capital | - | -9.70 | -31.40 | 18.13 | -12.93 | -8.57 |
| Quick Ratio | - | 0.81 | 12.23 | 11.43 | 9.93 | 14.09 |
| Current Ratio | - | 0.81 | 12.23 | 11.43 | 9.93 | 14.09 |
Cash flow, quarterly
| Metric | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 |
|---|
Revenue breakdown
| Pharmaceutical Preparations | 2024: 451.00K |
|---|---|
| Israel | 2024: 451.00K |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.10% | 0.0M | 4.4M | 8.38K |
| 2026-10-15 | 0.10% | 0.0M | 4.1M | 8.21K |
| 2026-09-30 | 0.15% | 0.0M | 4.1M | 16.22K |
| 2026-09-15 | 0.17% | 0.0M | 4.1M | 71.16K |
| 2026-08-31 | 0.27% | 0.0M | 4.1M | 70.43K |
| 2026-08-14 | 0.48% | 0.0M | 2.3M | 73.39K |
| 2026-07-31 | 1.06% | 0.0M | 2.3M | 116.34K |
| 2026-07-15 | 1.57% | 0.0M | 2.3M | 1.98M |
| 2026-06-30 | 0.41% | 0.0M | 2.3M | 1.94M |
| 2026-06-15 | 0.53% | 0.0M | 2.3M | 1.86M |
| 2026-05-29 | 0.42% | 0.0M | 2.3M | 1.89M |
| 2026-05-15 | 0.83% | 0.0M | 2.3M | 1.89M |
| 2026-04-30 | 29.46% | 0.7M | 2.3M | 1.88M |
| 2026-04-15 | 0.27% | 0.0M | 2.3M | 16.21K |
| 2026-03-31 | - | 0.0M | - | 178.24K |
| 2026-03-13 | 0.60% | 0.0M | 2.3M | 179.59K |
| 2026-02-27 | 0.72% | 0.0M | 2.3M | 176.65K |
| 2026-02-13 | 0.71% | 0.0M | 2.3M | 175.61K |
| 2026-01-30 | 2.30% | 0.1M | 2.3M | 175.53K |
| 2026-01-15 | 6.18% | 0.1M | 2.3M | 172.40K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-14 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-14 | SEC |
| 2026-08-05 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-05 | SEC |
| 2026-07-21 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-21 | SEC |
| 2026-06-30 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2025-12-31 | SEC |
| 2026-06-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-30 | SEC |
| 2026-06-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-29 | SEC |
| 2026-06-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-22 | SEC |
| 2026-05-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-22 | SEC |
| 2026-05-15 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-15 | SEC |
| 2026-05-07 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-07 | SEC |
| 2026-04-30 | NT 20-F | 2025-12-31 | SEC | |
| 2026-04-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-29 | SEC |
| 2026-03-23 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-23 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-20 | SEC |
| 2026-03-10 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-10 | SEC |
| 2026-02-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-02-27 | SEC |
| 2026-02-24 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-02-24 | SEC |
| 2026-02-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-02-23 | SEC |
| 2026-02-17 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-02-17 | SEC |
| 2026-01-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-28 | SEC |
| 2026-01-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-23 | SEC |
| 2026-01-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-23 | SEC |
| 2026-01-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-13 | SEC |
| 2026-01-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-13 | SEC |
| 2025-12-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-12-30 | SEC |
| 2025-12-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-12-29 | SEC |
| 2025-12-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-12-12 | SEC |
| 2025-12-05 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-12-05 | SEC |
| 2025-10-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-10-22 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| RHUMBLINE ADVISERS | 0.16% |
| GAMMA Investing LLC | 0.08% |
| UBS Group AG | 0.01% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 0.03% |
| Blackstone Alternative Multi-Strategy Fund | 0.00% |
OakChart. XTLB. Cached 15 minutes.
Some panels did not load: insider.